Investors
-
November 18, 2024Umecrine Cognition presents positive interim data from ongoing Phase 1b/2a study with golexanolone at the AASLD Liver Meeting in San DiegoSTOCKHOLM – November 18, 2024. Umecrine Cognition today announces that the company will present late-breaking data from a recent interim analysis...
-
October 17, 2024Umecrine Cognition attends INBC 2024 to present new preclinical data showing conserved dopamine signaling in Parkinson’s diseaseSTOCKHOLM – October [17], 2024. Umecrine Cognition today announces that the company will attend the 10th Edition of the International Conference...
-
July 10, 2024Umecrine Cognition raises MSEK 28.3 for the ongoing clinical development of golexanoloneSTOCKHOLM – July 10, 2024. Umecrine Cognition today announces that the company has performed a capital raise amounting to SEK 28,3 million...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.